Treatment of patients with advanced refractory or relapsed melanoma in a phase II study of tremelimumab (CP-675,206), an anti-ctla4 monoclonal antibody
J M Kirkwood, P Lorigan, P Hersey, A Hauschild, C Robert, D McDermott, J Gomez-Navarro, J Liang, C A Bulanhagui
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'Treatment of patients with advanced refractory or relapsed melanoma in a phase II study of tremelimumab (CP-675,206), an anti-ctla4 monoclonal antibody'. Together they form a unique fingerprint.